EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023
NEW YORK, Sept. 2, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023
EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023
Summary
Renal cell carcinoma (RCC) is a type of kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport waste molecules from the blood to the urine. The condition is asymptomatic in its initial stages, and as a result, people with RCC are often in the advanced stages of the disease by the time it is discovered. The initial symptoms of RCC often include blood in the urine, flank pain, a mass in the abdomen or flank, weight loss, fever, hypertension, night sweats, and a general feeling of being unwell. Kidney cancer is among the 10 most frequently occurring cancers in Western countries.
GlobalData epidemiologists forecast that there were 186,179 incident cases of RCC in the 8MM in 2013, and the number of incident cases will grow 6.25% over the next decade to 302,449 incident cases. In 2013, there were 593,228 prevalent cases of RCC in the 8MM. Each of the 8MM will see an increase in prevalent cases over the 10-year forecast period.
This forecast is supported by age- and sex-specific data for the incidence. The one- to five-year relative survival data, which were used for the five-year diagnosed prevalent cases forecast, are supported by country-specific, population-based studies that are nationally representative of the entire population in the respective markets. Additionally, in each of the 8MM, the analysis is strengthened by the use of a consistent methodology for the diagnosed incident cases forecast, using regression techniques, and is based on 15 years of country-specific historical data points pertaining to the age- and sex-specific diagnosed incidence of RCC.
Scope
- The Renal Cell Carcinoma (RCC) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for RCC in the eight major markets 8MM (US, France, Germany, Italy, Spain, UK, Japan, and urban China). It includes a 10-year epidemiological forecast for the diagnosed incident cases of RCC segmented by sex and age (in five-year age groups beginning at 20 years and ending at 85 years and older).- GlobalData epidemiologists also forecast the five-year diagnosed prevalent cases of RCC in the 8MM. Additionally, the report provides the RCC diagnosed incident cases, segmented by the stage at diagnosis, for the 8MM.- The RCC epidemiology report is written and developed by Masters- and PhD-level epidemiologists.- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
Reasons to buy
- Develop business strategies by understanding the trends shaping and driving the global RCC market.- Quantify patient populations in the global RCC market to improve product design, pricing, and launch plans.- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for RCC therapeutics in each of the markets covered.1 Table of Contents1 Table of Contents 42 Introduction 72.1 Catalyst 72.2 Upcoming Related Reports 73 Epidemiology 83.1 Disease Background 83.2 Risk Factors and Comorbidities 93.3 Global Trends 103.3.1 Incidence 103.3.2 Survival Rates for RCC - 8MM 133.4 Forecast Methodology 143.4.1 Sources Used 163.4.2 Sources Not Used 193.4.3 Forecast Assumptions and Methods, RCC Diagnosed Incident Cases 203.4.4 Forecast Assumptions and Methods, RCC Five-Year Diagnosed Prevalent Cases 203.4.5 Forecast Assumptions and Methods, RCC Clinical Stage at Diagnosis 213.5 Epidemiological Forecast for RCC (2013-2023) 223.5.1 Diagnosed Incident Cases of RCC 223.5.2 Age-Specific Diagnosed Incident Cases of RCC 243.5.3 Sex-Specific Diagnosed Incident Cases of RCC 263.5.4 Age-Standardized Diagnosed Incidence of RCC 283.5.5 Diagnosed Incident Cases of RCC by Clinical Stage at Diagnosis 303.5.6 Five-Year Diagnosed Prevalent Cases of RCC 313.6 Discussion 323.6.1 Epidemiological Forecast Insight 323.6.2 Limitations of the Analysis 333.6.3 Strengths of the Analysis 334 Appendix 354.1 Bibliography 354.2 About the Authors 384.2.1 Epidemiologists 384.2.2 Reviewers 384.2.3 Acting Director of Epidemiology 394.2.4 Global Head of Healthcare 404.3 About GlobalData 414.4 About EpiCast 414.5 Disclaimer 42
1.1 List of Tables
Table 1: RCC Clinical Stages at Diagnosis 9Table 2: Risk Factors and Comorbidities for RCC 10Table 3: Trends in the Age-Adjusted Incidence of Kidney Cancers in the US, Ages ?20 Years, 1993-2007 11Table 4: Trends in the Age-Adjusted Incidence of Kidney Cancers in the 5EU, Ages ?20 Years, 1993-2007 12Table 5: Trends in the Age-Adjusted Incidence of Kidney Cancers in Japan, Ages ?20 Years, 1993-2007 12Table 6: Trends in the Age-Adjusted Incidence of Kidney Cancers in Urban China, Ages ?20 Years, 1993-2007 13Table 7: Trends in the Five-Year Relative Survival (%) of Kidney Cancers in the 8MM, Both Sexes, 1993-2009 14Table 8: 8MM, Sources of Epidemiological Data Used for the Forecast for RCC Diagnosed Incident Cases 15Table 9: 8MM, Sources of Epidemiological Data Used for the Forecast for RCC Diagnosed Five-Year Prevalent Cases 15Table 10: 8MM, Sources of Epidemiological Data Used for the Segmentation of RCC Incident Cases by Clinical Stage at Diagnosis 16Table 11: 8MM, Diagnosed Incident Cases of RCC, Both Sexes, Ages ?20 Years, N, 2013-2023 23Table 12: 8MM, Age-Specific Diagnosed Incident Cases of RCC, Both Sexes, N (Row %), 2013 25Table 13: 8MM, Sex-Specific Diagnosed Incident Cases of RCC, Ages ?20 Years, N (Row %), 2013 27Table 14: 8MM, Five-Year Diagnosed Prevalent Cases of RCC, Both Sexes, Ages ?20 Years, N, 2013-2023 31
1.2 List of Figures
Figure 1: 8MM, Diagnosed Incident Cases of RCC, Both Sexes, Ages ?20 Years, N, 2013-2023 23Figure 2: 8MM, Age-Specific Diagnosed Incident Cases of RCC, Both Sexes, N, 2013 26Figure 3: 8MM, Sex-Specific Diagnosed Incident Cases of RCC, Ages ?20 Years, N, 2013 28Figure 4: 8MM, Age-Standardized Diagnosed Incidence of RCC (Cases per 100,000 Population), Ages ?20 Years, by Sex, 2013 29Figure 5: 8MM, Diagnosed Incident Cases of RCC by Clinical Stage at Diagnosis, Ages ?20 Years, N, 2013 30Figure 6: 8MM, Five-Year Diagnosed Prevalent Cases of RCC, Both Sexes, Ages ?20 Years, N, 2013-2023 32
To order this report: EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023 http://www.reportlinker.com/p02353373/EpiCast-Report-Renal-Cell-Carcinoma---Epidemiology-Forecast-to-2023.html
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article